Committed to patients with neuroendocrine tumors
9th Annual ENETS Conference

for the

Diagnosis and Treatment of Neuroendocrine Tumor Disease

7 - 9 March 2012
Copenhagen • Denmark
Welcome to Copenhagen

The ENETS Executive Committee welcomes you to its 9th Annual Conference and also to Copenhagen. In attending this premier global event, you join some of the most respected and dynamic researchers and key opinion leaders in the field of neuroendocrine tumor research and multidisciplinary management of the disease. Over the next two days, these expert specialists will be sharing the most cutting-edge research in the field today.

The European Neuroendocrine Tumor Society today claims close to 1,000 members located in more than 50 countries. We consider this a notable achievement for an organization dedicated to a rare disease. Again, I welcome everyone to our annual meeting and appreciate the distances traveled to be here.

While our 2011 conference in Lisbon drew positive feedback, the ENETS Executive Committee also considered requests to streamline the scientific program for this year’s conference. The meeting this year, for the first time, includes three parallel sessions. We are especially pleased, too, to offer delegates a nurses symposium, which many participants last year requested be made part of the official program. These parallel sessions, we hope, offer delegates more variety in content. We also increased the number of the Meet the Professor sessions, and are again offering the popular postgraduate course, which nearly doubled in participation from last year.

I am exceptionally proud to announce that the Society this year set a record in the number of abstracts received for the conference: 204. Likewise, we received 27 applications from young investigators for travel grants, and awarded 10. The review committee members for this work are encouraged by the level of scholarship in this new generation of NET researchers.

The 2012 ENETS Annual Conference is sponsored by the pharmaceutical firms Novartis, as platinum sponsor; Pfizer, as gold sponsor; Ipsen, as silver sponsor; and Lexicon as bronze sponsor. We thank them for their generous support. We also welcome PerkinEimer, CISBIO Bioassays, Covidien, IDB-Holland, Keocyt, and Thermo Fisher Scientific, all of which are exhibiting during the conference.

Philippe Ruszniewski, M.D., Ph.D.
Clichy, France
Chairman, European Neuroendocrine Tumor Society (ENETS)
Mark Your Calendars Now!

10th Annual ENETS Conference

for the Diagnosis and Treatment of Neuroendocrine Tumors

For more information, visit: www.neuroendocrine.net

6-8 March 2013 • Barcelona • Spain
**Thursday, 8 March 2012**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 3A: MANAGEMENT OF GEP GRADE 2 AND 3 NEOPLASMS</th>
<th>Session 3B: PATHWAYS AND NEW MOLECULAR TARGETS</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 – 15:00</td>
<td>Tivoli Congress Hall</td>
<td>Room Carstensen, lower level</td>
</tr>
<tr>
<td></td>
<td>Chair:</td>
<td>Chairs:</td>
</tr>
<tr>
<td></td>
<td><em>E. Raymond, Clichy, FRA</em></td>
<td><em>R. Salazar, Barcelona, ESP</em></td>
</tr>
<tr>
<td></td>
<td><em>F. Costa, Sao Paolo, BRA</em></td>
<td><em>J. Yao, Houston, TX, USA</em></td>
</tr>
<tr>
<td>14:30 – 15:00</td>
<td><strong>G2 NETs: Are they all the same?</strong></td>
<td><strong>RAF Signalling</strong></td>
</tr>
<tr>
<td></td>
<td><em>M. Pavel, Berlin, GER</em></td>
<td><em>N. Fazio, Milan, ITA</em></td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td><strong>G3, High-grade NEC: What are they and how to deal with them?</strong></td>
<td><strong>mTOR – AKT3</strong></td>
</tr>
<tr>
<td></td>
<td><em>E. Baudin, Villejuif, FRA</em></td>
<td><em>J. Yao, Houston, TX, USA</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Angiogenesis and VEGF inhibition</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>O. Casanovas, Barcelona, ESP</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>General Assembly</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 – 16:00</td>
<td>COFFEE BREAK and POSTER VIEWING</td>
<td>Room Carstensen, lower level</td>
</tr>
<tr>
<td>16:00 – 17:00</td>
<td><strong>GENERAL ASSEMBLY</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(for ENETS members only)</td>
<td></td>
</tr>
</tbody>
</table>

**17:30 – 19:00** **NOVARTIS SYMPOSIUM:**

- *The Expanding Palette of Therapeutic Options for the Treatment of Advanced Neuroendocrine Tumors*
(C125) A Pilot Study on the Immunohistochemical Expression of Chromogranin and/or Synaptophysin in Moderate to Poorly Differentiated Gastroenteropancreatic Carcinomas
T.W.H. Shek, Hong Kong, CHN

(C126) Surgical Treatment of Organic Hyperinsulinism
V. Shkarban, Kiev, UKR

(C127) Epidemiology of Neuroendocrine Tumors in Ontario: A 15-year Population-Based Study
S. Singh, Toronto, CAN

(C128) Survival of Patients with Neuroendocrine Cancers in Ontario Over the Last 15 Years
S. Singh, Toronto, CAN

(C129) Patterns of Care of Neuroendocrine Cancer in Ontario: Health Services Delivery
S. Singh, Toronto, CAN

(C130) Laparoscopic Surgery of Pancreatic Endocrine Tumors: Is There a Benefit?
M. Soloviy, Lviv, UKR

(C131) How Long to Continue Surveillance in Patients Following "Curative Resection" of Primary Small Bowel Tumors?
R. Srirajaskanthan, London, GBR

(C132) Resection of Primary Tumor Improves Survival in Small Bowel Neuroendocrine Tumors: A Single Center Experience
R. Srirajaskanthan, London, GBR

(C133) Survival and Cause of Death in Patients with Small Bowel Neuroendocrine Tumors
R. Srirajaskanthan, London, GBR

(C134) Does TNM Staging Classification Predict Survival in Patients with Small Bowel Neuroendocrine Tumors?
R. Srirajaskanthan, London, GBR

(C135) Salivary-Free Catecholamines Metabolites in Pheochromocytoma
A.M. Stefanescu, Bucharest, ROM

(C136) Swiss Neuroendocrine Tumor (SwissNET) Registry: Update After Three Years
C. Stettler, Bern, SUI

(C137) Unresectable Mesenteric Midgut NETs: Are They a Unique Prognostic Category?
J. Strosberg, Tampa, FL, USA

(C138) Co-existing Type-1 Gastric Neuroendocrine Tumors (NETs) and Adenocarcinoma in Autoimmune Associated Atrophic Gastritis
L. Tang, New York, NY, USA

(C139) Goblet Cell Appendiceal Neuroendocrine Tumors: Diagnosis, Recurrence Rates, Treatment and Survival. A Series of 37 Patients
C. Toumpanakis, London, GBR

(C140) International Survey for the Use of Biomarkers and Molecular Imaging in Neuroendocrine Tumors (NET): What we are Using in Daily Practice
C. Toumpanakis, London, GBR

(C141) Diagnostic Accuracy of Gallium-68 Somatostatin Receptor Positron Emission Tomography in Patients with Thoracic and Gastroenteropancreatic Neuroendocrine Tumors: A Meta-Analysis
G. Treglia, Rome, ITA

(C142) A Retrospective Analysis of Neuroendocrine Tumors (NETs) in West Azerbaijan of Iran
N. Valizadeh, Urmia, IRN

(C143) Tumor Response Assessment to Treatment With [177Lu-DOTATOC]Octreotate in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Differential Response of Bone Versus Soft Tissue Lesions
E.I. Van Vliet, Rotterdam, NED

(C144) Hyperammonemnic Encephalopathy in Neuroendocrine Tumor Resolved Through Liver Embolization: A Case Report
T. Vandenbroek, Antwerp, BEL

(C145) Neuroendocrine Carcinoma (NEC) and Composite Exocrine-Neuroendocrine Carcinoma (CENEC) of the Stomach: A Clinicopathological Review of 58 Cases
L. Vashakmadze, Moscow, RUS

(C146) Are all Metastatic Grade 3 WHO 2010 Neuroendocrine Carcinoma Poorly Differentiated?
F.L. Velayoudom-Cephise, Villejuif, FRA

(C147) Clinical and Prognostic Features of Rectal Neuroendocrine Tumors
B.M. Weinstock, New York, NY, USA

(C148) Metastatic Pancreatic Neuroendocrine Carcinoma: Does Aggressive Surgical Intervention Improve Outcome?
M. White, Southampton, GBR

(C149) Treatment of Small Bowel Neuroendocrine Tumor (NETS): A Single Center's Experience
E. Woltering, New Orleans, LA, USA

(C150) Update on the Observational Gastroenteropancreatic Neuroendocrine Tumors (GEPNET) Registry: An International Collaboration
S. Yalcin, Ankara, TUR

(C151) Successful Treatment with Everolimus of Functioning Liver Metastases From a Pancreatic Insulinoma
M.C. Zatelli, Ferrara, ITA
Friday, 9 March 2012

12:00 – 13:00  SESSION 6: CASE PRESENTATIONS FROM THE ENETS ADVISORY BOARD
   12:00 – 12:20  Incidental finding of a solid hypervascular 15 mm tumor in the pancreatic head in a 65-year-old woman
                  D. Bartsch, Marburg, Germany
   12:20 – 12:40  Hyperparathyroidism and Zollinger-Ellison syndrome in an 18-year-old man
                  R. Jensen, Bethesda, MD, USA
   12:40 – 13:00  Multiple small gastric ECLomas in a young woman with atrophic gastritis
                  G. Delle Fave, Rome, Italy

13:00 – 14:00  LUNCH and POSTER VIEWING
14:00 – 14:15  2012 Young Investigator Awards

14:15 – 16:15  SESSION 7: INTEGRATED NET MANAGEMENT (INTERACTIVE SESSION)
   Chair: B. Wiedenmann, Berlin, GER
   14:15 – 14:45  Pancreas NET/C
                  P. Ruszniewski, Clichy, FRA
   14:45 – 15:15  GI-NET/C
                  K. Öberg, Uppsala, SWE
   15:15 – 16:15  Burning Questions
                  B. Wiedenmann, Berlin, GER

<table>
<thead>
<tr>
<th>PRO</th>
<th>CON</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeted Therapies (as first line)</td>
<td>R. Jensen, Bethesda, MD, USA</td>
</tr>
<tr>
<td>PRRT (as first line)</td>
<td>T. Meyer, London, GBR</td>
</tr>
<tr>
<td>Biomarkers</td>
<td>J. Yao, Houston, TX, USA</td>
</tr>
<tr>
<td>E. Baudin, Villejuif, FRA</td>
<td>D. Kwekkeboom, Rotterdam, NED</td>
</tr>
<tr>
<td>D. Kwekkeboom, Rotterdam, NED</td>
<td>M. Pavel, Berlin, GER</td>
</tr>
</tbody>
</table>

Personal

Tumours have specific characteristics and behaviours that may be best treated with personalised medicine. We’re focused on transforming treatment by targeting the right drug at the right time for each patient.

Focused on what truly matters.

Pfizer Oncology
(C70) Comparison of the Automated Chromogranin A Assay Using KRYPTOR Instrumentation With the Manual IRMA Assay of CisBio
C.M. Korse, Amsterdam, NED

(C71) mTOR Expression in Primary Pancreatic Neuroendocrine Tumors and Their Metastases
N. Kozlov, Moscow, RUS

(C72) Pasireotide and Octreotide LAR was an Effective Combination in a Patient With Small Intestinal NET With Hypokalemia and a High Level of VIP
G. Kozlovavc, Uppsala, SWE

(C73) Gastric Neuroendocrine Tumor Type 1 Associated with Autoimmune Polyglandular Syndrome Type 3B: A Case Report
I. Kruljac, Zagreb, CRO

(C74) Role of Ga-68 Somatostatin Receptor PET/CT in the Assessment of Response to Radiofrequency Ablation in Hepatic Metastases of Neuroendocrine Tumors
H. Kulkarni, Bad Berka, GER

(C75) Efficacy of Combined Peptide Receptor Radionuclide Therapy and Radiofrequency Ablation for the Management of Hepatic Metastases of Neuroendocrine Tumors
H. Kulkarni, Bad Berka, GER

(C76) Safety and Efficacy of Peptide Receptor Radionuclide Therapy after Liver Transplantation in Metastatic Neuroendocrine Tumors
H. Kulkarni, Bad Berka, GER

(C77) Efficacy of Telotristat Etiprate in Refractory Carcinoid Syndrome: Results of a Randomized, Placebo-controlled, Multicenter Study
M. Kulke, Boston, MA, USA

(C78) Expression of Cocaine- and Amphetamine-Regulated Transcript is Associated with Worse Survival in Small Bowel Carcinoid Tumors
K. Landerholm, Jönköping, SWE

(C79) Endoscopic Ultrasound-Guided Fine Needle Tissue Acquisition (EUS-FNQA) Using a 19-G Needle for Histological Grading of Pancreatic Endocrine Tumors (PETs): A Prospective Study
A. Larghi, Rome, ITA

(C80) Insulin Autoimmune Syndrome Mimicking insulinoma: A Challenging Diagnosis
F. Lugli, Rome, ITA

(C81) Determinants of Long-Term Outcome for Rectal NETs from a Large German Multicentre Cohort
S. Maasberg, Berlin, GER

(C82) Single Institutional Series of Neuroendocrine Tumors Managed in the AUSn Capital Territory
L. Malik, Garrants, AUS

(C83) Cachexia in Pancreatic Neuroendocrine Tumors: A Comparison with Pancreatic Adenocarcinoma
M. Malathi, Mumbai, IND

(C84) Case Report: A Rare Cause of Retroperitoneal Fibrosis Responding to Steroids
D. Mandair, Birmingham, GBR

(C85) Effectiveness of Transarterial Embolization in Neuroendocrine Tumors
D. Mandair, Birmingham, GBR

(C86) Diagnostic and Prognostic Role of 68Ga-DOTATATE PET in Patients With Neuroendocrine Tumors
F. Marcello, Naples, ITA

(C87) Difficulties in Diagnosis and Management of Neuroendocrine Tumors of the Head and Neck: A Case Report
A. Markovich, Moscow, RUS

(C88) Limitations of Chromogranin A in Clinical Practice
V. Marotta, Naples, ITA

(C89) Pancreatic Neuroendocrine Tumors: Retrospective Analysis of 44 Cases
P. Marques, Lisbon, POR

(C90) The Good, the Bad, the Unexpected
S. Martin, Bucharest, ROM

(C91) Chromogranin A (CgA) in the Diagnosis and Monitoring of Patients with Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NET): A Single-Institution Experience
S. Massironi, Milan, ITA

(C92) Tie-2 and Angiopoietin-2 Plasma Levels as New Diagnostic Markers for Patients with Neuroendocrine Tumors. Data from One Clinical Center
G. Melen-Mucha, Lodz, POL

(C93) Insulinomas in Children
M. Melikyan, Moscow, RUS

(C94) Left Pancreatectomy for Neuroendocrine Pancreatic Tumors
A.C. Milantettu, Padova, ITA

(C95) Metastatic Midgut Carcinoid Tumors: 20-years Experience in a Single Center
L. Moletta, Padova, ITA

(C96) Pancreatic Neuroendocrine Tumors Associated With Mesenchimal Neoplasms of the GI Tract
L. Moletta, Padova, ITA

(C97) Effect of Dacarbazine Chemotherapy in Well-Differentiated Neuroendocrine Tumors
D. Müller, Marburg, GER
Conference organization:
ENETS Office
c/o Charité - University Hospital
Campus Virchow-Klinikum
Hepatology and Gastroenterology
Augustenburger Platz 1
13353 Berlin, Germany

tel +49 (0)30 450-553 996 (general information)
+49 (0)170 9492 487 (hotels)
fax +49 (0)30 450-565 996
www.neuroendocrine.net
enets-annual-conference@charite.de

Scientific organizing committee:
Philippe Ruszniewski  Clichy  FRA
Guido Rindi  Rome  ITA
Kjell Öberg  Uppsala  SWE
Bertram Wiedenmann  Berlin  GER
Martyn Caplin  London  GBR
Dermot O’Toole  Clichy  FRA
Massimo Falconi  Verona  ITA
Beata Kos-Kudła  Katowice  POL
Ramon Salazar  Barcelona  ESP

Conference Venue
Tivoli Hotel & Congress Center
Arnir Magnnssons Gade 2-4
DK-1577 Copenhagen V

tel +45 4599 0000
www.tivolicongresscenter.dk
Thursday, 8 March 2012

<table>
<thead>
<tr>
<th>7:30 – 9:00</th>
<th>Meet the Professor</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Limited entrance; prior online registration and payment required</strong></td>
<td></td>
</tr>
<tr>
<td>Management of medullary thyroid cancer (sponsored by Pfizer Pharmaceuticals)</td>
<td>Rooms 11 &amp; 12, 2nd floor</td>
</tr>
<tr>
<td>A.M. Colao, Naples, ITA</td>
<td></td>
</tr>
<tr>
<td>Peritoneal carcinomatosis: surgical and medical management (sponsored by Ipsen)</td>
<td>Room Dansetten, 1st floor</td>
</tr>
<tr>
<td>R. Kianmanesh, Reims, FRA</td>
<td></td>
</tr>
<tr>
<td>Lung NETs (sponsored by Ipsen)</td>
<td>Room Divanen, 2nd floor</td>
</tr>
<tr>
<td>E. Lim, London, GBR</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9:00 – 9:15</th>
<th>Conference Welcome and Introduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tivoli Congress Hall, ground floor</td>
<td></td>
</tr>
<tr>
<td>P. Ruszniewski, Clichy, FRA</td>
<td></td>
</tr>
<tr>
<td>U. Knigge, Copenhagen, DEN</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9:15 – 10:45</th>
<th>SESSION 1: IMAGING – HOW MUCH IS REALLY NEEDED AND HOW MUCH CAN WE AFFORD?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairs: D. O’Toole, Clichy, FRA; A. Sundin, Stockholm, SWE</td>
<td></td>
</tr>
<tr>
<td>9:15 – 9:35</td>
<td>CT scan including perfusion and MRI including diffusion</td>
</tr>
<tr>
<td>V. Vilgrain, Clichy, FRA</td>
<td></td>
</tr>
<tr>
<td>9:35 – 9:55</td>
<td>Current challenges for the endoscopist</td>
</tr>
<tr>
<td>A. Larghi, Rome, ITA</td>
<td></td>
</tr>
<tr>
<td>9:55 – 10:15</td>
<td>Nuclear and molecular imaging</td>
</tr>
<tr>
<td>L. Bodei, Milan, ITA</td>
<td></td>
</tr>
<tr>
<td>10:15 – 10:45</td>
<td>The clinician’s view and discussion</td>
</tr>
<tr>
<td>U. Pape, Berlin, GER</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:45 – 11:00</th>
<th>2012 ENETS Life Achievement Award:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recipient: S. Lamberts, Rotterdam, NED</td>
<td></td>
</tr>
<tr>
<td>Dedication: W. de Herder, Rotterdam, NED</td>
<td></td>
</tr>
<tr>
<td>Chair: P. Ruszniewski, Clichy, FRA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11:00 – 11:30</th>
<th>COFFEE BREAK and POSTER VIEWING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Columbine Room, ground level</td>
<td></td>
</tr>
<tr>
<td>Harlekin Room, ground level</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11:30 – 12:30</th>
<th>SESSION 2: SELECTED ABSTRACTS - BASIC SCIENCE RELATED TO CANCER BIOLOGY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairs: G. Rindi, Rome, ITA; A. Kjaer, Copenhagen, DEN</td>
<td></td>
</tr>
<tr>
<td>11:30 – 11:45</td>
<td>Alternative Splicing and Differential Gene Expression in Pancreatic NETs</td>
</tr>
<tr>
<td>C. Grötzinger, Berlin, GER</td>
<td></td>
</tr>
<tr>
<td>11:45 – 12:00</td>
<td>Orexins Exert a Pro-Apoptotic Effect on Neuroendocrine Tumors (NETs) in an Ex Vivo Culture Model of Tissue Slices</td>
</tr>
<tr>
<td>M. Palazzo, Clichy, FRA</td>
<td></td>
</tr>
<tr>
<td>12:00 – 12:15</td>
<td>Genome-Wide Expression Profiling Reveals Downregulation of OTP and CD44 and Upregulation of RET as Indicators of Poor Prognosis in Lung Carcinoids</td>
</tr>
<tr>
<td>D. Swarts, Maastricht, NED</td>
<td></td>
</tr>
<tr>
<td>12:15 – 12:30</td>
<td>The First Neuroendocrine Tumor Methylome Using Methylation-Specific Immunoprecipitation Followed by Second Generation Sequencing - MeDIP-seq</td>
</tr>
<tr>
<td>A. Feber, London, GBR</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12:30 – 13:00</th>
<th>HOT NEWS IN NETs</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. Jensen, Bethesda, MD, USA</td>
<td></td>
</tr>
</tbody>
</table>

| 13:00 – 14:30 | LUNCH AND POSTER VIEWING |
(C98) Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) in North American Cohort of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)
B. Naray, Iowa City, IA, USA

(C99) Single-Center Treatment Outcomes in Patients (pts) with High Grade Neuroendocrine Carcinoma of the Uterine Cervix (cNEC)
B. Naray, Iowa City, IA, USA

(C100) Long-Term Outcomes in 50 Consecutive Patients with Neuroendocrine Tumors of the Pancreas
T. Natoli, Saitama, JAP

(C101) Pelvic Carcinoid Tumor Recurrence Treated by Laparoscopic Ultrasonography Guided Laparoscopic Resection
H. Nielsen, Odense, DEN

(C102) Effects of Transarterial Chemoembolization of Liver Metastases from Neuroendocrine Tumors on Clinical Outcome
S. Ognjanovic, Belgrade, SRB

(C103) A Case Report of a Patient with Metastatic Cervical Paraganglioma Responding to the Tyrosine Kinase Inhibitor Sunitinib
O. Oikonomidou, London, GBR

(C104) Methylguanine DNA Methyl Transferase (MGMT) Expression Predicts Response to Temozolomide in Patients with Digestive Neuroendocrine Tumors (NETs)
H. Olivia, Clichy, FRA

(C105) Intrapancreatic Accessory Spleen (IPAS) Misdiagnosed as Nonfunctioning Pancreatic Neuroendocrine Tumor (PNET): A Case Report and Characterization of a Syndrome Based on Systematic Review of the Literature
E. Oster, Tel Aviv, ISR

(C106) Pattern and Clinical Predictors of Lymph Node Involvement in Pancreatic Neuroendocrine Tumors (PanNETs)
S. Partelli, Verona, ITA

(C107) Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Symptomatic Carcinoid Syndrome: Preliminary Results of an Ongoing Phase 2, Multicenter, Open-label, Serial-ascending, European Study
M. Pavel, Berlin, GBR

(C108) Progression-Free Survival by Prior Somatostatin Analog Use and Primary Tumor Site and Updated Safety Results in Patients With Advanced Neuroendocrine Tumors and a History of Carcinoid Syndrome: A RADIANT-2 Analysis
M. Pavel, Berlin, GBR

(C109) Effect of Everolimus on Pharmacokinetics of Octreotide LAR in Patients With Advanced Neuroendocrine Tumors: A RADIANT-2 Analysis
M. Pavel, Berlin, GBR

(C110) Diagnostic Features and Management Outcomes in Bronchopulmonary Neuroendocrine Tumors: A Clinical Study of 116 Patients
M. Pericleous, London, GBR

(C111) Quality of Life in Patients With Neuroendocrine Tumors: A Cross-Sectional Study
L.M. Plum, Copenhagen, DEN

(C112) Well-Differentiated Neuroendocrine Tumors (WDNETs) and Carcinoid Syndrome (CS): A Retrospective Analysis of 110 Patients from Istituto Nazionale Tumori Milano
S. Pusceddu, Milano, ITA

(C113) A Prospective Evaluation of the Effects of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans
D. Raines, New Orleans, LA, USA

(C114) Diagnosis and Management of Insulinomas in a Tertiary Referral Center: A 10-Year Review
V. Ramachandran, Kamatake, IND

(C115) Clinical and Psychometric Validation of the Disease-Specific Questionnaire Module (EORTC QLQ-GINET21) in Assessing Quality of Life of Patients with Neuroendocrine Tumors
J. Ramage, London, GBR

(C116) Contrast-Enhanced Ultrasound (CEUS) is a Helpful Tool to Predict the Effectiveness of Somatostatin Analogues in Patients With Liver Metastases from Neuroendocrine Tumors
V. Ramundo, Naples, ITA

(C117) Benefit of Octreotide LAR in Patients With Neuroendocrine Midgut Tumors Who Previously Progressed on Placebo Therapy: Two Cases From the PROMID Study
A. Ranke, Marburg, GBR

(C118) An Esophageal Gastrointestinal Stromal Tumor (GIST) in a Patient with MEN-1 Related Pancreatic Gastrinoma
R.E. Rossi, Milan, ITA

(C119) Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
M. Sansovini, Forli, ITA

(C120) Effective Treatment of a Metastatic Thymic Neuroendocrine Tumor with Capecitabine and Temozolomide: A Case Report
V. SarangaPerry, Tampa, FL, USA

(C121) A Rare Case of Cushing Syndrome Caused by an Ectopic ACTH-Secreting Pancreatic Neuroendocrine Tumor in a Patient with Von Hippel-Lindau Disease
L. Sbarlata, Rozzano, ITA

(C122) Lack of Accuracy of Circulating Chromogranin A in the Preoperative Diagnosis of Lung Neuroendocrine Tumors
G. Scarpetti, Perugia, ITA

(C123) Epidemiology of Neuroendocrine Tumors in France: The PRONET Study
J.Y. Scoazec, Lyon, FRA

(C124) Chromogranin A (CgA) and Pancreastatin (PcSt) as Predictors of Peptide Receptor Radionuclide Therapy (PRRT) Outcomes in Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)
N. Sharma, Iowa City, IA, USA
Friday, 9 March 2012

**7:30 - 8:30**  
**Meet the Professor**  
*Limited entrance; prior online registration and payment required*

**Use of TKI's management of side effects**  
(sponsored by Pfizer Pharmaceuticals)  
*Rooms 13 & 14, 2nd floor*

*M. Schmidinger, Vienna, AUT*

**Paraganglioma and malignant pheochromocytoma**  
*Room Dansetten, 1st floor*

*D. Ferone, Genoa, ITA*

**Management of rare functional tumors (insulinoma, glucagonoma, VIPOMA)**  
(sponsored by Pfizer Pharmaceuticals)  
*Rooms 11 & 12, 2nd floor*

*D. O'Toole, Chlicky, FRA*

---

**8:30 – 10:00**  
**SESSION 4A:**  
*Tivoli Congress Hall, ground floor*

**MEN-1**  
*Chairs: S. Marx, Bethesda, MD, USA  
W. de Herder, Rotterdam, NED*

8:30 – 8:50  
**MEN-1 gene and genetic diagnosis**  
*S. Marx, Bethesda, MD, USA*

8:50 – 9:10  
**Treatment of hyperparathyroidism: When and how?**  
*M.L. Brandi, Florence, ITA*

9:10 – 9:30  
**Duodenal and pancreatic surgery: The end of a controversy?**  
*D. Bartsch, Marburg, GER*

9:30 – 9:45  
**Recommendations for patient follow-up**  
*B. Skogseid, Uppsala, SWE*

9:45 – 10:00  
**Q & A**

---

**8:30 – 10:00**  
**SESSION 4B:**  
*BASIC SCIENCE – WHAT’S NEW?*

*Room Carstensen, lower level*

**Chairs: A. Scarpa, Verona, ITA  
N. Papadopoulos, Baltimore, MD, USA**

8:30 – 8:50  
**Genomics – new generation sequencing: What’s it good for?**  
*N. Papadopoulos, Baltimore, MD, USA*

8:50 – 9:10  
**SSTR mutants: Any significance?**  
*J. Castano, Cordoba, ESP*

9:10 – 9:30  
**Circulating tumor cells: Do they matter?**  
*M. Khan, London, GBR*

9:30 – 10:00  
**MIR: Any good for NETs?**  
*A. Scarpa, Verona, ITA*

---

**10:00 – 11:00**  
**COFFEE BREAK and POSTER VIEWING**  
*Columbine Room, ground level Harlekin Room, ground level*

---

**11:00 – 12:00**  
**SESSION 5: SELECTED ABSTRACTS - CLINICAL RESEARCH**  
*Chairs: E. Mitry, Saint Cloud, FRA; D.J. Kweekkeboom, Rotterdam, NED*

11:00 – 11:15  
**Glucagon-Like Peptide 1 Receptor (GLP-1R) Imaging for the Preoperative Localization of Benign Insulinomas in 30 Patients**  
*E. Christ, Bern, SUI*

11:15 – 11:30  
**YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients With Type 1 Gastric Carcinoids**  
*H. Waldum, Trondheim, NOR*

11:30 – 11:45  
**Genetic Alterations in Glucagon Cell Adenomatosis**  
*T. Henopp, Tübingen, GER*

11:45 – 12:00  
**Pattern and Clinical Predictors of Lymph Node Involvement in Pancreatic Neuroendocrine Tumors (PanNETs)**  
*S. Partelli, Verona, ITA*
(C42) Treatment of Unresectable Metastatic GEP NETs: Data From a Prospective Observational Unicentric Study
P.J. Fonseca, Oviedo, ESP

(C43) Second Primary Tumor in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): Data From a Retrospective Observational Unicentric Study
P.J. Fonseca, Oviedo, ESP

(C44) YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients With Type 1 Gastric Carcinoids
R. Fossmark, Trondheim, NOR

(C45) The Role of Chemotherapy in the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The Large Experience of the Spanish National Tumor Registry (RGETNE)
R. Garcia-Carbonero, Sevilla, ESP

(C46) Depression and Carcinoid Syndrome: Is There Any Relationship? A Cross-Sectional Study
J. Garcia-Hernandez, London, GBR

(C47) Assessment of Quality of Life, Coping Strategies and Beliefs in NET Patients
J. Garcia-Hernandez, London, GBR

(C48) Predictors of Survival Following Y90 DOTATOC/DOTATATE Therapy
T. Gilbert, Liverpool, GBR

(C49) Ten Years of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Evolution of Classification and Correlation With Follow-up in 50 Patients
F. Grillo, Genova, ITA

(C50) B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation With Disease Behavior
F. Grimaldi, Udine, ITA

(C51) Right Hemicolectomy in the Treatment of Patients With Appendiceal Neuroendocrine Tumors: Does Size Matter?
S. Grozinsky-Glasberg, Jerusalem, ISR

(C52) An Increasing Incidence of GEP-NETs in Chengdu City With a Population of 14 Million in China
L. Guo, Chengdu, CHI

(C53) Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors (PNETs): Updated Results From a Single-Center Case Control Study
T. Halfdanarson, Iowa City, IA, USA

(C54) Laparoscopic Surgery of Pancreatic Neuroendocrine Tumors: Results from a Tertiary Care Institution
S. Haugvik, Oslo, NOR

(C55) Efficacy of Everolimus and Tolerability with Long-Term Use
M. Heelfeld, Berlin, GER

(C56) Ileal GEP-NEN in Mother and Son an Option for Familial Disease
J. Hennings, Umeå, SWE

(C57) Genetic Alterations in Glucagon Cell Adenomatosis
T. Henopp, Tübingen, GER

(C58) Peptide Receptor Radioligand Therapy for Neuroendocrine Tumors in GER: First Results of a Multiinstitutional Cancer Registry
D. Hörsch, Bad Berka, GER

(C59) Effect of Open-Label Everolimus After Disease Progression in Patients With Advanced Neuroendocrine Tumors: A RADIANT-2 Analysis
D. Hörsch, Bad Berka, GER

(C60) Clinical Manifestations of Patients With Pancreatic Cells Hyperplasia
T.L. Hwang, Tao-Yuan, TWN

(C61) kValidation of Chromogranin A Assays in Patients with Neuroendocrine Tumors
L.B. Høj, Aarhus, DEN

(C62) A Case of ACTH-Secreting Bronchial Carcinoid
D. Iacovazzo, Rome, ITA

(C63) Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales
A. Johns, Tedworth, GBR

(C64) Evaluation of 68Ga-DOTATAZ and 68Ga-DOTATATE PET/CT in Somatostatin Exosing Organs and Tumors
L. Kabasakal, Istanbul, TUR

(C65) Thoracic and Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) and Ectopic Adrenocorticotropic (ACTH) Syndrome (EAS)
K. Kamp, Rotterdam, NED

(C66) Cost-Effectiveness of Sunitinib in Patients (Pts) With Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the NED
A. Kansi, Bethesda, MD, USA

(C67) Detection of Liver Metastases and Prognostic Value of Functional and Anatomical Imaging in Patients With Neuroendocrine Tumors
U. Kniige, Copenhagen, DEN

(C68) Association Between Activin A & NT-pro-BNP in Carcinoid Heart Disease and Intestinal Desmoplasia in Patients With Metastatic Midgut and PeVic NET
D. Knight, London, GBR

(C69) Hypoglycemic Syndrome in 30 Patients
I. Komerdus, Moscow, RUS
The titles of all accepted abstracts, along with first authors, are listed here:

**Basic science related to cancer biology**

(B1) A 67-Year-Old Woman With a Carcinoid Tumor of the Coccyx With Liver Metastases  
T. Angelopoulos, Athens, GRE

(B2) Expression of UCH-L1 in PETs and Its Implications  
Y.J. Chen, Beijing, CHI

(B3) Olfactory Receptor 51E1 is a Novel Potential Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors  
T. Cui, Uppsala, SWE

(B4) Activation of Hedgehog Pathway in Neuroendocrine Tumor  
M. Dong, Houston, TX, USA

(B5) mir-123-5p and Let-7 are Down-Regulated in Carcinoid Tumors  
K. Dissing, Copenhagen, DEN

(B6) SOMscan: Towards a Ga-68-labeled Pan-Somatostatin PET Imaging Probe Based on SOM230 (Pasireotide)  
M. Fan, Freiburg, GER

(B7) Alterations of Global and Gene-Specific DNA Methylation in Midgut Carcinoids  
O. Fotouhi, Stockholm, SWE

(B8) HIF-1 Determines the Metastatic Potential of the GEP-NET Cell Line BON-1  
K. Freitag de Molina, Berlin, GER

(B9) Bronchial Carcinoid Response to mTOR Inhibitors Depends on mTOR Expression Levels  
T. Gagliano, Ferrara, ITA

(B10) CK19 Expression in ATH-Producing Extrapituitary Neuroendocrine Neoplasms is a Negative Prognostic Factor  
L.A. Gurevich, Moscow, RUS

(B11) Morphological Characteristics of Pancreatic Tumors in Children and Young Patients  
L.A. Gurevich, Moscow, RUS

(B12) Expression of Chromosome 18 Related Tumor Suppressors Proteins in Ileal Neuroendocrine Tumors  
T. Henopp, Tubingen, GER

(B13) Proliferative Activity is Not Associated with Tumor Aggressiveness in Ileal Neuroendocrine Tumors  
T. Henopp, Tubingen, GER

(B14) MANECs Among Colorectal Signet Ring Cell Carcinomas  
G. Hermann, Zerlin, ISR

(B15) Postoperative Complications after Previous Peptide-Receptor Radionuclide Therapy  
D. Kaeemmer, Bad Berka, GER

(B16) Alternative Splicing and Differential Gene Expression in Pancreatic NETs  
J. Köner, Berlin, GER

(B17) CUX1 Mediates Progression of Neuroendocrine Tumors  
S. Krug, Marburg, GER

(B18) Comparative Expression Analysis of Somatostatin Receptor Subtypes in Human Neuroendocrine Tumors Using Two Sets of New Monoclonal Antibodies  
C. Lambertini, Basel, SUI

(B19) The Somatostatin Analogue Octreotide Inhibits Growth of Neuroendocrine Tumor Cells by Triggering Janus Faced Proteins  
S. Li, Uppsala, SWE

(B20) Role of MicroRNAs in Small Intestine Neuroendocrine Tumors  
S. Li, Uppsala, SWE

(B21) Bifunctional ShRNA-imPDX-1 Therapy Prevents Hypoglycemic Death From Insulinoma in Mice  
S. Liu, Houston, TX, USA

(B22) Differential Expression of Markers in a Midgut Carcinoid Tissue Microarray  
E. Liu, Nashville, TN, USA

(B23) Activation of EGFR and c-Met Signaling Pathways in Well-Differentiated Neuroendocrine Tumors of the Small Intestine  
E. Liu, Nashville, TN, USA

(B24) Succinate Dehydrogenase (SDHB): A New Marker of Malignancy in Midgut Carcinoids?  
M. Milione, Milano, ITA

(B25) mTOR Inhibitors Hamper Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures  
M. Minoia, Ferrara, ITA

(B26) Comparison of Prognostic Capacity for Overall Survival (OS) and Disease-Free Survival (DFS) of Neuroendocrine Tumors (NETs) Classifications: 2010 WHO, TNM Staging-ENETS and AJCC  
N. Mulet-Margalef, Barcelona, ESP

(B27) Status of DNA Repair and Cell Proliferation Markers in High Grade Neuroendocrine Carcinoma of the Uterine Cervix (cNEC) Compared to Small Cell Carcinoma of the Lung (SCLC)  
B. Naray, Iowa, Iowa, USA

(B28) Combined Blockade of Several Signalling Pathways Shows Marked Anti-Tumor Potential in Two Novel Mouse Phaeochromocytoma Cell Lines  
S. Ncard, London, GBR
(B29) Role of Somatostatin Analogues in the Management of Merkel Cell Carcinoma: A Case Report
K. Oriova, Moscow, RUS

(B30) Orexins Exert a Pro-Apoptotic Effect on Neuroendocrine Tumors (NETs) in an Ex Vivo Culture Model of Tissue Slices
M. Palazzo, Clichy, FRA

(B31) Sunitinib in a MEN-1 Patient With Small Cell Neuroendocrine Tumor of the Thymus
G. Palmeri, Naples, ITA

(B32) Differential Claudin-1 Gene Expression in Neural Crest-Derived Tumors of Common Embryological Origin
B. Philip, Goldcoast, AUS

(B33) Effect of the Combined Administration of mTOR Inhibitor and Dopamine or Somatostatin Analogues in Human Bronchial Neuroendocrine Cell Line
R. Pivenello, Naples, ITA

(B34) Immunohistochemical (IHC) Overexpression of Succinate Dehydrogenase (SDHB) as Prognostic Factor in Sporadic Pheochromocytomas/Paragangliomas (P/P)
S. Piscaglia, Milano, ITA

(B35) Cost-Effectiveness of Sunitinib in Patients with Advanced or Metastatic Pancreatic Neuroendocrine Tumors in POR
M. Soares, Oeiras, POR

(B36) Correlation Between mTOR Pathway and Clinical Outcomes in Patients With Well-Differentiated Neuroendocrine Tumors Treated With Everolimus
F. Spada, Milan, ITA

(B37) Genome-Wide Expression Profiling Reveals Downregulation of OTP and CD44 and Upregulation of RET as Indicators of Poor Prognosis in Lung Carcinoids
D. Swarts, Maastricht, NED

(B38) Activation of cdk4/Cyclind D1 and the Associated Attenuation of Rb Function in Pancreatic Neuroendocrine Tumors (Pan-NETs)
L. Tang, New York, NY, USA

(B39) The First Neuroendocrine Tumor Methylome Using Methylation-Specific Immunoprecipitation Followed by Second Generation Sequencing in MeDIP-seq
C. Thirwell, London, GBR

(B40) Pheochromocytoma Molecular Analysis After Maternal Transmission of SDHD Mutation Elucidates Mechanism of Parent-of-Origin Effect
E. Tobias, Glasgow, GBR

(B41) Ovarian Primary Neuroendocrine Tumor Combined With a Monodermal Teratoma: A Case Report
N. Vazifezadeh, Urmia, IRN

(B42) Invasive, Moderately Differentiated Neuroendocrine Carcinoma of the Larynx
N. Vazifezadeh, Urmia, IRN

(B43) Neuroendocrine and Ductal Breast Cancer Coexistence: An Unusual Case Report
M. Vasilasatizis, Athens, GRE

Clinical Research

(C1) Malignant Carotid Body Tumors (CBTs), Clinical Presentation, Investigations and Their Management
M. Ahmed, Riyadh, SAU

(C2) Challenges in the Management of a Disseminated Malignant Abdominal Paragangliom (MPGL)
M. Ahmed, Riyadh, SAU

(C3) Primary Neuroendocrine Tumor of the Parathyroid
M. Ahmed, Riyadh, SAU

(C4) Management of an Advanced Pancreatic Neuroendocrine Tumor
M. Ahmed, Riyadh, SAU

(C5) Lymph-Nodal Merkel Cell Carcinoma (MCC) in the Absence of Primary Tumor: Regression of the Primary or Lymph-Nodal Primitivity? Report of a Series With Favorable Prognostic Behavior
M. Albertelli, Genova, ITA

(C6) Efficacy and Safety of Everolimus in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
M.R. Ambrosio, Ferrara, ITA

(C7) Duodenal Carcinoid Tumors Are Associated With Increased Survival and Earlier Detection When Compared With Jejunal or Ileal Carcinoids: A Population Based Study
S. Amin, New York, NY, USA

(C8) Symptomatic Control of Neuroendocrine Tumors With Everolimus
H. Bainbridge, London, GBR

(C9) Everolimus and Octreotide LAR in Neuroendocrine Tumors: An I.T.M.O. (ITAn Trials in Medical Oncology) Group Study
E. Bajetta, Monza, ITA

(C10) The Role of Image and Chromogranin A Level at Diagnosis: A Portuguese Review of 19 Patients
P. Barata, Lisbon, POR

(C11) Czech Neuroendocrine Tumor Registry - 28 Months Results
J. Bankmanova, Prague, CZE

(C12) CK19 and KIT Immunostaining is a Useful Adjunct to Ki-67-Based Grading of Pancreatic NET: A Study on Matched Cytological and Histological Samples
G. Belleviseti, Napoli, ITA

(C13) FOLFOX Regimen for Clinically Aggressive Neuroendocrine Tumors: About One Case
L. Bengrine-Lefevre, Paris, FRA
Efficacy of Everolimus in Patients With Metastatic Insulinomas and Refractory Hypoglycemia: For the French Group of Endocrine Tumors (GETE-Renaten)  
V. Bernard, Villejuif, FRA

EUS-FNA for Pancreatic Neuroendocrine Tumors: A Single Referral Centre Experience  
D. Berretty, Udine, ITA

Establishment of a Multidisciplinary Tumor Board for Patients With Neuroendocrine Neoplasms  
A. Bianchi, Rome, ITA

Overall Survival of Well-Differentiated Neuroendocrine Tumors Evaluated by F-18-FDG-PET  
T. Biderup, Copenhagen, DEN

Neuroendocrine Carcinomas (NEC) of the Pancreas: A Land of Hope?  
L. Bonienga, Negar (VR), ITA

Gastric Carcinoids: Prevalence in Europe and USA, and Rationale for Treatment With YF476, a Gastrin Receptor Antagonist  
M. Boyce, London, GBR

Bevercizumab Plus Octreotide and Metronomic Capecitabine in Patients With Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors: The KELBEVOT Multicenter Phase II Study  
M.P. Brzzi, Orbassano, ITA

Paraneoplastic Neurological Syndrome in a Patient with a Pancreatic Well-Differentiated Endocrine Tumor  
M.P. Brzzi, Orbassano (TO), ITA

The Bone Scintigram in Patients With Neuroendocrine Tumors - A Series of 12 Cases  
M. Carlote, Bucharest, ROM

Liver Transplantation for Metastatic Neuroendocrine Tumor: A Case Series and Proposed Selection Criteria  
G. Chan, London, CAN

Octreotide Long-Acting ReleaseTherapy for Patients With Functional and Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Retrospective Analysis in Chang-Gung Memorial Hospital  
H. Chia-Hsun, Taoyuan, TWN

Glucagon-Like Peptide 1 Receptor (GLP-1R) imaging for the Preoperative Localization of Benign Insulinomas in 30 Patients  
E. Christ, Bern, SWITZ

Treatment, Survival and Prognostic Markers in Patients With Thymic Carcinoids: A Clinicopathologic Study of 28 Cases  
J. Crona, Uppsala, SWE

Low Diagnostic Accuracy of Tumor Markers for the Annual Screening of Pancreatic Neuroendocrine Tumors in MEN-1 Patients  
J. De Laat, Utrecht, NED

Trans-Arterial Embolization (TAE) is the Best Locoregional Treatment Option for Patients with Liver Metastases from Neuroendocrine Tumors  
M. Del Prete, Naples, ITA

Initial Experience of Biological Stability and Image Timing of Ga-68 DOTANOC in Somatostatin Receptor (sstR) Expressing Organ and Tumor  
E. Demirci, Istanbul, TUR

Clinical Case of a Man With ACTH-Ectopic Syndrome and Autosomal-Dominant Polycystic Disease  
A. Dreval, Moscow, RUS

Metastatic Neuroendocrine Carcinoma (mNETs)  
L. Edwards, Southampton, GBR

Treatment of Malignant Neuroendocrine Tumors of the Hepatopancreatododenal Region  
A. Egorov, Moscow, RUS

Carcinoid Tumor of Common Bile Duct (CBD) Misdiagnosed as Cholangiocarcinoma  
A. Eshie Okezie, Urmia, IRN

Gallium 68 DOTATATE PET CT Assessment of Patients (pts.) With Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs): First Experience in a Multidisciplinary Team in ARG (Argentum Group)  
M. Elef, Buenos Aires, ARG

Comparison of Transarterial Liver-Directed Therapies (LDT) for Low-Grade Metastatic Neuroendocrine Tumors (mNETs)  
E. Engelmann, Iowa City, IA, USA

Long-Acting Somatostatin Analogues are Highly Effective in Patients With Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors  
A. Faggiano, Naples, ITA

Long-Term Stable Disease With Everolimus in a Patient With Advanced Pancreatic Neuroendocrine Tumor Enrolled in RADIANT-1  
J. Farkertby, Uppsala, SWITZ

Outcomes After Liver Resection and Multidisciplinary Management of Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases  
A. Fehr, London, CAN

Analysis of the AJCC/ENETS Staging Classification for Midgut Neuroendocrine Tumors  
M. Feldman, Tampa, FL, USA

Should Primary Hyperparathyroidism at Age Below 40 Years Always Lead to Search for MEN-1, Despite Presence of Other Plausible Explanations?  
U. Feldt-Rasmussen, Copenhagen, DEN

Everolimus Controlled Resistant Hypoglycemia in Malignant Insulinoma  
A. Ferrero, Orbassano, ITA